留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型

徐佰国 向慧玲 韩涛

徐佰国, 向慧玲, 韩涛. 慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型[J]. 临床肝胆病杂志, 2021, 37(2): 433-436. DOI: 10.3969/j.issn.1001-5256.2021.02.039
引用本文: 徐佰国, 向慧玲, 韩涛. 慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型[J]. 临床肝胆病杂志, 2021, 37(2): 433-436. DOI: 10.3969/j.issn.1001-5256.2021.02.039
XU BG, XIANG HL, HAN T. Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(2): 433-436. DOI: 10.3969/j.issn.1001-5256.2021.02.039
Citation: XU BG, XIANG HL, HAN T. Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B[J]. J Clin Hepatol, 2021, 37(2): 433-436. DOI: 10.3969/j.issn.1001-5256.2021.02.039

慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型

DOI: 10.3969/j.issn.1001-5256.2021.02.039
基金项目: 

天津市卫生行业重点攻关项目 16KG152

详细信息
    作者简介:

    徐佰国(1983—),男,主治医师,主要从事肝硬化相关并发症研究

    通讯作者:

    韩涛,hantaomd@126.com

  • 作者贡献声明:向慧玲负责课题设计,拟定写作思路;徐佰国负责文献资料查阅及分析撰写论文;韩涛负责修改论文,指导撰写文章并最后定稿。
  • 中图分类号: R512.62;R735.7

Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B

  • 摘要: HBV感染是肝硬化和肝癌的主要病因之一。抗病毒药物的使用明显降低了慢性乙型肝炎患者肝癌的发生风险,但部分长期服用抗病毒药物患者,最终仍发生肝癌。因此,有必要对此类患者发生肝癌的风险进行早期识别和预测。当前根据肝硬化、年龄、性别、肝硬度、病毒学、血清学指标、饮酒情况、糖尿病病史等危险因素,形成了一些慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型,这些预测模型包括mREACH-B、PAGE-B、mPAGE-B、APA-B、CAMD、AASL、REAL-B等。综述了慢性乙型肝炎患者抗病毒治疗过程中发生肝癌的风险预测模型研究进展。
  • 表  1  CHB患者口服抗病毒治疗过程中发生肝癌的风险预测模型简表

    预测模型 作者 发表年限 国家及地区 纳入人群 入组标准 预测因素 HCC预测效能 是否外部验证
    mREACH-B Jung等[19] 2015 韩国 接受抗病毒治疗848例未接受抗病毒治疗460例 CHB患者或肝功能Child-Pugh A级患者(包括曾经、正在、未抗病毒患者) 年龄、性别、ALT、HBeAg状态、肝硬度 3、5年AUC为0.813、0.795(抗病毒人群)
    PAGE-B Papatheodoridis等[20] 2016 希腊 推导组1325例验证组490例 接受ETV和/或TDF治疗≥1年的CHB患者 年龄、性别、血小板计数 第5年C指数为0.82、0.82 (推导队列、验证队列)
    mPAGE-B Kim等[21] 2018 韩国 推导组2001例验证组1000例 接受ETV或TDF治疗≥1年的CHB患者 年龄、性别、血小板计数、白蛋白 5年AUC为0.82、0.82(推导队列、验证队列)
    APA-B Chen等[22] 2017 中国台湾 推导组883例验证组442例 ETV治疗12个月以上初治CHB患者 年龄、血小板计数、治疗12个月后AFP水平 2、3、5年AUC为0.939、0.892、0.862(验证队列)
    CAMD Hsu等[23] 2018 中国台湾 推导组23 851例验证组19 321例 接受ETV或TDF治疗的CHB患者 肝硬化、年龄、男性和糖尿病 第1、2、3年C指数为0.74、0.75、0.75(验证队列)
    AASL-HCC Yu等[24] 2019 韩国 推导组944例验证组298例 首次接受ETV或TDF治疗CHB患者 年龄、白蛋白、性别、肝硬化 第5年C指数为0.802、0.805(推导队列、验证队列)
    REAL-B Yang等[25] 2019 中国台湾 推导组5365例验证组2683例 接受口服抗病毒药物治疗的亚洲CHB(包括亚裔美国人和本土亚洲人) 性别、年龄、酒精摄入量、糖尿病、基线是否肝硬化、血小板计数、AFP 第3、5、10年AUC为0.83、0.81、0.81(验证队列)
    下载: 导出CSV
  • [1] Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4): 524-548.
    [2] FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
    [3] FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011
    [4] CHAN SL, WONG VW, QIN S, et al. Infection and cancer: The case of hepatitis B[J]. J Clin Oncol, 2016, 34(1): 83-90. DOI: 10.1200/JCO.2015.61.5724
    [5] LIU K, CHOI J, LE A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(9): 1037-1048. DOI: 10.1111/apt.15499
    [6] WONG GL, WONG VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39): 6515-6522. DOI: 10.3748/wjg.v19.i39.6515
    [7] ARENDS P, SONNEVELD MJ, ZOUTENDIJK R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians[J]. Gut, 2015, 64(8): 1289-1295. DOI: 10.1136/gutjnl-2014-307023
    [8] SERPER M, TADDEI TH, MEHTA R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality[J]. Gastroenterology, 2017, 152(8): 1954-1964. DOI: 10.1053/j.gastro.2017.02.040
    [9] KIM BH, LIM YS, KIM EY, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population[J]. J Gastroenterol Hepatol, 2018, 33(2): 475-483. DOI: 10.1111/jgh.13848
    [10] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
    [11] TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
    [12] OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
    [13] Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B[J]. Clin Mol Hepatol, 2016, 22(1): 18-75. DOI: 10.3350/cmh.2016.22.1.18
    [14] CADIER B, BULSEI J, NAHON P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States[J]. Hepatology, 2017, 65(4): 1237-1248. DOI: 10.1002/hep.28961
    [15] CHANG TT, LAI CL, KEW YOON S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2010, 51(2): 422-430. DOI: 10.1002/hep.23327
    [16] LAI CL, GANE E, LIAW YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25): 2576-2588. DOI: 10.1056/NEJMoa066422
    [17] MARCELLIN P, HEATHCOTE EJ, BUTI M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23): 2442-2455. DOI: 10.1056/NEJMoa0802878
    [18] LEE HW, YOO EJ, KIM BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol, 2014, 109(8): 1241-1249. DOI: 10.1038/ajg.2014.157
    [19] JUNG KS, KIM SU, SONG K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology, 2015, 62(6): 1757-1766. DOI: 10.1002/hep.28115
    [20] PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035
    [21] KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5): 1066-1073. DOI: 10.1016/j.jhep.2018.07.018
    [22] CHEN CH, LEE CM, LAI HC, et al. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir[J]. Oncotarget, 2017, 8(54): 92431-92441. DOI: 10.18632/oncotarget.21369
    [23] HSU YC, YIP TC, HO HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2): 278-285. DOI: 10.1016/j.jhep.2018.02.032
    [24] YU JH, SUH YJ, JIN YJ, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 865-872. DOI: 10.1097/MEG.0000000000001357
    [25] YANG HI, YEH ML, WONG GL, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3): 389-399. DOI: 10.1093/infdis/jiz477
    [26] WU S, KONG Y, PIAO H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38(6): 1045-1054. DOI: 10.1111/liv.13623
    [27] CHIANG HH, LEE CM, HU TH, et al. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir[J]. Liver Int, 2018, 38(11): 1997-2005. DOI: 10.1111/liv.13889
    [28] WONG GL, CHAN HL, TSE YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B[J]. J Hepatol, 2018, 69(4): 793-802. DOI: 10.1016/j.jhep.2018.05.009
    [29] KIM BG, PARK NH, LEE SB, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B[J]. Liver Int, 2018, 38(12): 2269-2276. DOI: 10.1111/liv.13938
    [30] HSU YC, JUN T, HUANG YT, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 48(10): 1128-1137. DOI: 10.1111/apt.15006
  • 加载中
表(1)
计量
  • 文章访问数:  30
  • HTML全文浏览量:  18
  • PDF下载量:  27
  • 被引次数: 0
出版历程
  • 收稿日期:  2020-08-03
  • 修回日期:  2020-09-15
  • 刊出日期:  2021-02-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回